Prevention of Endometrial Hyperplasia in Postmenopausal Women with Intrauterine Progesterone

Publisher Website
Google Scholar
Abstract
Progestogens are used in postmenopausal women to oppose the stimulatory effects of estrogen on the endometrium and thereby to prevent endometrial hyperplasia. However, this therapy results in withdrawal bleeding and may also cause mood disturbances1 and reduce serum concentrations of high-density lipoprotein cholesterol. We describe the effects of an intrauterine device releasing 65 μg of progesterone per day (Progestasert, Alza, Palo Alto, Calif.) in 10 postmenopausal women (age, 44 to 57 years). The women also received continuous therapy with oral conjugated equine estrogens (0.625 mg per day). These women had previously been taking cyclic oral estrogen and progestogens and had regular withdrawal bleeding, but they had discontinued treatment at least 30 days before the study. The study was approved by the institutional review board, and all women gave informed consent.

This publication has 2 references indexed in Scilit: